Nicole Onetto
Director/Board Member bei BOLT BIOTHERAPEUTICS, INC.
Vermögen: 30 807 $ am 31.03.2024
Profil
Nicole M.
Onetto is an Independent Non-Executive Director at Basilea Pharmaceutica AG, an Independent Director at Bolt Biotherapeutics, Inc., and a Director at CDR-Life Inc. She previously held positions at Bristol Myers Squibb Co., ImmunoGen, Inc., YM BioSciences, Inc., Sierra Oncology, Inc., Sunesis Pharmaceuticals, Inc., Ontario Institute for Cancer Research, NBE-Therapeutics AG, Viracta Therapeutics, Inc., Gilead Sciences, Inc., OSI Pharmaceuticals, Inc., NeXstar Pharmaceuticals, Inc., and ZymoGenetics, Inc. She has also earned graduate and undergraduate degrees from the University of Montréal and a doctorate from Université de Paris 5 René Descartes.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
BASILEA PHARMACEUTICA AG
0,01% | 31.12.2022 | 737 ( 0,01% ) | 30 807 $ | 31.03.2024 |
19.04.2023 | 0 ( -.--% ) | - $ | 31.03.2024 | |
12.06.2023 | 0 ( -.--% ) | - $ | 31.03.2024 |
Aktive Positionen von Nicole Onetto
Unternehmen | Position | Beginn |
---|---|---|
BASILEA PHARMACEUTICA AG | Director/Board Member | 27.04.2017 |
BOLT BIOTHERAPEUTICS, INC. | Director/Board Member | 14.12.2021 |
CDR-Life Inc.
CDR-Life Inc. BiotechnologyHealth Technology CDR-Life Inc. is a Swiss biotherapeutics company that develops novel immunotherapies to target the power of the immune system specifically to tumor cells. CDR-Life is based in Schlieren, Switzerland, and was founded in 2017 by Leonardo Borras, Christian Leisner, Dominik Escher, Rouven Bingel-Erlenmeyer, and Konstantin von Schulthess. The company's proprietary antibody platform targets intracellular tumor antigens presented on the major histocompatibility complex (MHC) with high affinity and specificity, which allows them to develop a pipeline of first-in-class therapeutics across a broad range of solid tumors. The company is backed by leading cross-Atlantic investors and has an existing collaboration and licensing agreement with Boehringer Ingelheim for a novel antibody fragment therapy to treat macular degeneration. Christian Leisner has been the CEO since 2017. | Director/Board Member | 08.12.2022 |
Ehemalige bekannte Positionen von Nicole Onetto
Unternehmen | Position | Ende |
---|---|---|
VIRACTA THERAPEUTICS, INC. | Director/Board Member | 08.06.2023 |
VIRACTA THERAPEUTICS, INC. | Director/Board Member | 01.02.2021 |
NBE-Therapeutics AG
NBE-Therapeutics AG BiotechnologyHealth Technology NBE-Therapeutics AG operates as biotechnology company. It develops next-generation ADCs improving treatment options for cancer patients. The company was founded by Ulf Grawunder in 2012 and is based in Basel, Swizerland. | Director/Board Member | 01.01.2021 |
SIERRA ONCOLOGY, INC. | Director/Board Member | 22.11.2019 |
IMMUNOGEN, INC. | Director/Board Member | 09.12.2016 |
Ausbildung von Nicole Onetto
University of Montréal | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 6 |
---|---|
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
GILEAD SCIENCES, INC. | Health Technology |
IMMUNOGEN, INC. | Health Technology |
BASILEA PHARMACEUTICA AG | Health Technology |
BOLT BIOTHERAPEUTICS, INC. | Health Technology |
VIRACTA THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 10 |
---|---|
OSI Pharmaceuticals, Inc.
OSI Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OSI Pharmaceuticals, Inc. manufactured and develope dpharmaceutical drugs. The company was founded in 1983 and was headquartered in Farmingdale, NY. | Health Technology |
NeXstar Pharmaceuticals, Inc.
NeXstar Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NeXstar Pharmaceuticals, Inc. was a commercial biopharmaceutical company engaged in the discovery, development, manufacture and marketing of proprietary pharmaceutical products to treat life-threatening and other serious diseases. The firm was located in Boulder, CO. | Health Technology |
ZymoGenetics, Inc.
ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | Health Technology |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Health Technology |
Sierra Oncology, Inc.
Sierra Oncology, Inc. BiotechnologyHealth Technology Sierra Oncology, Inc. was a clinical stage drug development company of therapeutics for the treatment of cancer. The firm focused on advanced targeted therapeutics for the treatment of patients with significant unmet medical needs in hematology and oncology. Its product Momelotinib, a selective and orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor with a differentiated therapeutic profile in myelofibrosis encompassing robust constitutional symptom improvements. The company was founded in May 2003 and is headquartered in San Mateo, CA. | Health Technology |
Sunesis Pharmaceuticals, Inc.
Sunesis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA. | Health Technology |
Ontario Institute for Cancer Research
Ontario Institute for Cancer Research Hospital/Nursing ManagementHealth Services Ontario Institute for Cancer Research provides research on the prevention, early detection, diagnosis, and treatment of cancer. It offers Innovation programs, like cancer stem cell, innovation in target validation, and smarter imaging, Technology programs, like drug discovery, genome technologies, informatics and bio-computing, imaging translation, and tranformative pathology, and Translation programs. The company was founded by Calvin R. Stiller in December 2005 and is headquartered in Toronto, Canada. | Health Services |
Université de Paris 5 René Descartes | Consumer Services |
NBE-Therapeutics AG
NBE-Therapeutics AG BiotechnologyHealth Technology NBE-Therapeutics AG operates as biotechnology company. It develops next-generation ADCs improving treatment options for cancer patients. The company was founded by Ulf Grawunder in 2012 and is based in Basel, Swizerland. | Health Technology |
CDR-Life Inc.
CDR-Life Inc. BiotechnologyHealth Technology CDR-Life Inc. is a Swiss biotherapeutics company that develops novel immunotherapies to target the power of the immune system specifically to tumor cells. CDR-Life is based in Schlieren, Switzerland, and was founded in 2017 by Leonardo Borras, Christian Leisner, Dominik Escher, Rouven Bingel-Erlenmeyer, and Konstantin von Schulthess. The company's proprietary antibody platform targets intracellular tumor antigens presented on the major histocompatibility complex (MHC) with high affinity and specificity, which allows them to develop a pipeline of first-in-class therapeutics across a broad range of solid tumors. The company is backed by leading cross-Atlantic investors and has an existing collaboration and licensing agreement with Boehringer Ingelheim for a novel antibody fragment therapy to treat macular degeneration. Christian Leisner has been the CEO since 2017. | Health Technology |